AR092670A1 - Derivados de quinazolinona - Google Patents
Derivados de quinazolinonaInfo
- Publication number
- AR092670A1 AR092670A1 ARP130103430A ARP130103430A AR092670A1 AR 092670 A1 AR092670 A1 AR 092670A1 AR P130103430 A ARP130103430 A AR P130103430A AR P130103430 A ARP130103430 A AR P130103430A AR 092670 A1 AR092670 A1 AR 092670A1
- Authority
- AR
- Argentina
- Prior art keywords
- denotes
- replaced
- hal
- atoms
- piperazinyl
- Prior art date
Links
- 125000004429 atom Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- -1 4-isopropyl-1-piperazinyl Chemical group 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001738 Nervous System Trauma Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 125000005959 diazepanyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 208000028412 nervous system injury Diseases 0.000 abstract 1
- 125000003566 oxetanyl group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12006707 | 2012-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092670A1 true AR092670A1 (es) | 2015-04-29 |
Family
ID=47002492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103430A AR092670A1 (es) | 2012-09-26 | 2013-09-25 | Derivados de quinazolinona |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9388142B2 (OSRAM) |
| EP (1) | EP2900643B1 (OSRAM) |
| JP (1) | JP6276769B2 (OSRAM) |
| KR (1) | KR102200628B1 (OSRAM) |
| CN (1) | CN104662006B (OSRAM) |
| AR (1) | AR092670A1 (OSRAM) |
| AU (1) | AU2013324681B2 (OSRAM) |
| BR (1) | BR112015006524A8 (OSRAM) |
| CA (1) | CA2886000C (OSRAM) |
| ES (1) | ES2654464T3 (OSRAM) |
| IL (1) | IL237840A (OSRAM) |
| MX (1) | MX362855B (OSRAM) |
| RU (1) | RU2650107C2 (OSRAM) |
| SG (1) | SG11201502120XA (OSRAM) |
| WO (1) | WO2014048532A1 (OSRAM) |
| ZA (1) | ZA201502838B (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX356509B (es) | 2011-12-22 | 2018-05-30 | Alios Biopharma Inc | Nucleósidos sustituidos, nucleótidos y análogos de los mismos. |
| MX346147B (es) | 2012-03-07 | 2017-03-09 | Inst Of Cancer Research: Royal Cancer Hospital (The) | Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico. |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| ES2597757T3 (es) | 2012-05-25 | 2017-01-20 | Janssen Sciences Ireland Uc | Nucleósidos de uracilespirooxetano |
| PE20151433A1 (es) | 2012-12-21 | 2015-10-16 | Alios Biopharma Inc | Nucleosidos sustituidos, nucleotidos y analogos de los mismos |
| JP6456392B2 (ja) | 2013-09-11 | 2019-01-23 | インスティチュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル | ３−アリール−５−置換イソキノリン−１−オン化合物及びその治療的使用 |
| EP3206689B1 (en) | 2014-10-14 | 2021-12-08 | La Jolla Institute of Allergy & Immunology | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| CN107286169B (zh) * | 2016-04-05 | 2020-11-24 | 北京四环制药有限公司 | 端锚聚合酶抑制剂 |
| CN106432103A (zh) * | 2016-09-14 | 2017-02-22 | 信阳师范学院 | 一种喹唑酮类化合物及其制备方法 |
| WO2018204176A1 (en) * | 2017-05-01 | 2018-11-08 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof |
| EP3733206A4 (en) * | 2017-12-27 | 2021-12-01 | Japanese Foundation For Cancer Research | ANTI-CANCER AGENTS |
| ES2998084T3 (en) * | 2017-12-27 | 2025-02-19 | Japanese Found For Cancer Res | Novel dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor |
| JP2022546010A (ja) * | 2019-08-28 | 2022-11-02 | エフ．ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス疾患の処置及び予防のための新規キナゾリン化合物 |
| WO2025111705A1 (en) * | 2023-11-30 | 2025-06-05 | Waverley Pharma Inc. | Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors |
| WO2025221809A1 (en) * | 2024-04-16 | 2025-10-23 | Eluciderm Inc. | 2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3046871A1 (de) * | 1980-12-12 | 1982-07-22 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue chinazolinone, ihre herstellung und ihre verwendung als arzneimittel |
| DE3166627D1 (en) | 1980-12-12 | 1984-11-15 | Thomae Gmbh Dr K | Pyrimidones, their preparation and medicines containing them |
| GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| WO1999018077A1 (en) | 1997-10-02 | 1999-04-15 | Eisai Co., Ltd. | Fused pyridine derivatives |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| CN1431999A (zh) | 2000-05-31 | 2003-07-23 | 阿斯特拉曾尼卡有限公司 | 具有血管损伤活性的吲哚衍生物 |
| JP2004502766A (ja) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管損傷剤としてのコルヒノール誘導体 |
| RU2003103603A (ru) | 2000-07-07 | 2004-08-20 | Энджиоджен Фармасьютикалз Лимитед (Gb) | Производные колхинола в качестве ингибиторов ангиогенеза |
| AU2003252314A1 (en) | 2002-08-09 | 2004-02-25 | Kyorin Pharmaceutical Co., Ltd. | 4-substituted quinazoline-8-carboxyamide derivative and pharmaceutically acceptable addition salt thereof |
| MX2007010965A (es) * | 2005-03-09 | 2007-09-19 | Merck & Co Inc | Antagonistas de canales de calcio de tipo t de quinazolinona. |
| JP5545955B2 (ja) | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体 |
| CN105859639A (zh) * | 2009-03-18 | 2016-08-17 | 雷斯韦洛吉克斯公司 | 新的抗炎剂 |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| CN103228141B (zh) | 2010-09-03 | 2016-04-20 | 拜耳知识产权有限责任公司 | 取代的稠合的嘧啶酮和二氢嘧啶酮 |
-
2013
- 2013-08-27 MX MX2015003570A patent/MX362855B/es active IP Right Grant
- 2013-08-27 ES ES13756318.5T patent/ES2654464T3/es active Active
- 2013-08-27 CN CN201380050421.9A patent/CN104662006B/zh active Active
- 2013-08-27 EP EP13756318.5A patent/EP2900643B1/en active Active
- 2013-08-27 WO PCT/EP2013/002577 patent/WO2014048532A1/en not_active Ceased
- 2013-08-27 RU RU2015115576A patent/RU2650107C2/ru active
- 2013-08-27 CA CA2886000A patent/CA2886000C/en active Active
- 2013-08-27 US US14/431,632 patent/US9388142B2/en active Active
- 2013-08-27 AU AU2013324681A patent/AU2013324681B2/en active Active
- 2013-08-27 BR BR112015006524A patent/BR112015006524A8/pt not_active Application Discontinuation
- 2013-08-27 JP JP2015533466A patent/JP6276769B2/ja active Active
- 2013-08-27 KR KR1020157010728A patent/KR102200628B1/ko not_active Expired - Fee Related
- 2013-08-27 SG SG11201502120XA patent/SG11201502120XA/en unknown
- 2013-09-25 AR ARP130103430A patent/AR092670A1/es active IP Right Grant
-
2015
- 2015-03-19 IL IL237840A patent/IL237840A/en active IP Right Grant
- 2015-04-24 ZA ZA2015/02838A patent/ZA201502838B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2654464T3 (es) | 2018-02-13 |
| KR20150063474A (ko) | 2015-06-09 |
| CA2886000C (en) | 2020-11-10 |
| RU2015115576A (ru) | 2016-11-20 |
| CA2886000A1 (en) | 2014-04-03 |
| AU2013324681A1 (en) | 2015-05-07 |
| HK1210777A1 (en) | 2016-05-06 |
| MX362855B (es) | 2019-02-20 |
| RU2650107C2 (ru) | 2018-04-09 |
| CN104662006B (zh) | 2017-10-24 |
| SG11201502120XA (en) | 2015-04-29 |
| KR102200628B1 (ko) | 2021-01-08 |
| US9388142B2 (en) | 2016-07-12 |
| MX2015003570A (es) | 2015-06-22 |
| IL237840A (en) | 2017-05-29 |
| AU2013324681B2 (en) | 2017-08-10 |
| CN104662006A (zh) | 2015-05-27 |
| EP2900643A1 (en) | 2015-08-05 |
| US20150239850A1 (en) | 2015-08-27 |
| BR112015006524A2 (pt) | 2017-07-04 |
| JP6276769B2 (ja) | 2018-02-07 |
| ZA201502838B (en) | 2017-11-29 |
| EP2900643B1 (en) | 2017-09-27 |
| WO2014048532A1 (en) | 2014-04-03 |
| BR112015006524A8 (pt) | 2019-08-20 |
| JP2015535831A (ja) | 2015-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092670A1 (es) | Derivados de quinazolinona | |
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| AR092366A1 (es) | Derivados de (aza-)isoquinolinona | |
| AR097087A1 (es) | Derivados de oxoquinazolinil-butanamida | |
| AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
| CU20160052A7 (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| MX2017010062A (es) | [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2 ,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. | |
| AR111233A1 (es) | Inhibidores de tyk2, usos y métodos para la producción de los mismos | |
| UY35398A (es) | Compuestos de biarilamida como inhibidores de cinasa | |
| AR089944A1 (es) | Derivados de tetrahidro-quinazolinona | |
| MX2020000404A (es) | Inhibidores de tirosina quinasa de bazo (syk). | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| AR081628A1 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR093759A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| CR20170092A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR094553A1 (es) | Formas de oxadiazolpirazina | |
| AR093143A1 (es) | Compuestos de 2-aminopiridina | |
| AR090103A1 (es) | Derivados ciclicos de diaminopirimidina | |
| AR100333A1 (es) | Derivados de heterociclil-butanamida | |
| AR097086A1 (es) | Derivados 1,3-disustituidos de ciclopentano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |